vs

Side-by-side financial comparison of GYRE THERAPEUTICS, INC. (GYRE) and Open Lending Corp (LPRO). Click either name above to swap in a different company.

GYRE THERAPEUTICS, INC. is the larger business by last-quarter revenue ($37.2M vs $19.3M, roughly 1.9× Open Lending Corp). On growth, Open Lending Corp posted the faster year-over-year revenue change (134.0% vs 33.4%). Open Lending Corp produced more free cash flow last quarter ($-3.3M vs $-5.8M). Over the past eight quarters, GYRE THERAPEUTICS, INC.'s revenue compounded faster (17.0% CAGR vs -20.7%).

GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.

Open Library is an online project intended to create "one web page for every book ever published". Created by Aaron Swartz, Brewster Kahle, Alexis Rossi, Anand Chitipothu, and Rebecca Hargrave Malamud, Open Library is a project of the Internet Archive, a nonprofit organization. It has been funded in part by grants from the California State Library and the Kahle/Austin Foundation. Open Library provides online digital copies in multiple formats, created from images of many public domain, out-of...

GYRE vs LPRO — Head-to-Head

Bigger by revenue
GYRE
GYRE
1.9× larger
GYRE
$37.2M
$19.3M
LPRO
Growing faster (revenue YoY)
LPRO
LPRO
+100.5% gap
LPRO
134.0%
33.4%
GYRE
More free cash flow
LPRO
LPRO
$2.5M more FCF
LPRO
$-3.3M
$-5.8M
GYRE
Faster 2-yr revenue CAGR
GYRE
GYRE
Annualised
GYRE
17.0%
-20.7%
LPRO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
GYRE
GYRE
LPRO
LPRO
Revenue
$37.2M
$19.3M
Net Profit
$-1.4M
Gross Margin
95.3%
76.0%
Operating Margin
0.3%
3.9%
Net Margin
-3.7%
Revenue YoY
33.4%
134.0%
Net Profit YoY
-340.1%
EPS (diluted)
$-0.01
$-0.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GYRE
GYRE
LPRO
LPRO
Q4 25
$37.2M
$19.3M
Q3 25
$30.6M
$24.2M
Q2 25
$26.8M
$25.3M
Q1 25
$22.1M
$24.4M
Q4 24
$27.9M
$-56.9M
Q3 24
$25.5M
$23.5M
Q2 24
$25.2M
$26.7M
Q1 24
$27.2M
$30.7M
Net Profit
GYRE
GYRE
LPRO
LPRO
Q4 25
$-1.4M
Q3 25
$5.9M
$-7.6M
Q2 25
$1.6M
$1.0M
Q1 25
$3.7M
$617.0K
Q4 24
$569.0K
Q3 24
$2.9M
$1.4M
Q2 24
$4.5M
$2.9M
Q1 24
$9.9M
$5.1M
Gross Margin
GYRE
GYRE
LPRO
LPRO
Q4 25
95.3%
76.0%
Q3 25
94.7%
78.0%
Q2 25
95.7%
78.2%
Q1 25
95.9%
75.1%
Q4 24
95.8%
111.0%
Q3 24
96.2%
73.9%
Q2 24
96.9%
78.6%
Q1 24
96.4%
81.3%
Operating Margin
GYRE
GYRE
LPRO
LPRO
Q4 25
0.3%
3.9%
Q3 25
22.7%
-31.9%
Q2 25
8.1%
4.6%
Q1 25
10.3%
3.1%
Q4 24
2.4%
138.0%
Q3 24
16.6%
7.9%
Q2 24
12.7%
14.9%
Q1 24
29.7%
23.8%
Net Margin
GYRE
GYRE
LPRO
LPRO
Q4 25
-3.7%
Q3 25
19.4%
-31.3%
Q2 25
5.9%
4.1%
Q1 25
16.9%
2.5%
Q4 24
2.0%
Q3 24
11.2%
6.1%
Q2 24
18.0%
10.9%
Q1 24
36.6%
16.5%
EPS (diluted)
GYRE
GYRE
LPRO
LPRO
Q4 25
$-0.01
$-0.00
Q3 25
$0.03
$-0.06
Q2 25
$0.00
$0.01
Q1 25
$0.00
$0.01
Q4 24
$0.00
$-1.20
Q3 24
$0.01
$0.01
Q2 24
$0.01
$0.02
Q1 24
$0.03
$0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GYRE
GYRE
LPRO
LPRO
Cash + ST InvestmentsLiquidity on hand
$52.4M
$176.6M
Total DebtLower is stronger
$84.8M
Stockholders' EquityBook value
$106.0M
$75.0M
Total Assets
$166.1M
$236.7M
Debt / EquityLower = less leverage
1.13×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GYRE
GYRE
LPRO
LPRO
Q4 25
$52.4M
$176.6M
Q3 25
$60.0M
$222.1M
Q2 25
$54.4M
$230.7M
Q1 25
$29.9M
$236.2M
Q4 24
$26.7M
$243.2M
Q3 24
$25.1M
$250.2M
Q2 24
$25.1M
$248.0M
Q1 24
$37.4M
$247.0M
Total Debt
GYRE
GYRE
LPRO
LPRO
Q4 25
$84.8M
Q3 25
$134.4M
Q2 25
$136.1M
Q1 25
$137.9M
Q4 24
$139.7M
Q3 24
$141.5M
Q2 24
$143.3M
Q1 24
$143.2M
Stockholders' Equity
GYRE
GYRE
LPRO
LPRO
Q4 25
$106.0M
$75.0M
Q3 25
$101.9M
$72.8M
Q2 25
$92.0M
$78.9M
Q1 25
$68.1M
$79.8M
Q4 24
$63.3M
$78.1M
Q3 24
$63.2M
$220.5M
Q2 24
$60.4M
$216.8M
Q1 24
$56.6M
$211.5M
Total Assets
GYRE
GYRE
LPRO
LPRO
Q4 25
$166.1M
$236.7M
Q3 25
$159.4M
$287.7M
Q2 25
$152.6M
$296.7M
Q1 25
$129.8M
$304.2M
Q4 24
$125.4M
$296.4M
Q3 24
$125.2M
$395.7M
Q2 24
$120.9M
$382.8M
Q1 24
$122.0M
$380.6M
Debt / Equity
GYRE
GYRE
LPRO
LPRO
Q4 25
1.13×
Q3 25
1.84×
Q2 25
1.72×
Q1 25
1.73×
Q4 24
1.79×
Q3 24
0.64×
Q2 24
0.66×
Q1 24
0.68×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GYRE
GYRE
LPRO
LPRO
Operating Cash FlowLast quarter
$-5.6M
$-3.2M
Free Cash FlowOCF − Capex
$-5.8M
$-3.3M
FCF MarginFCF / Revenue
-15.5%
-16.8%
Capex IntensityCapex / Revenue
0.4%
0.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-180.0K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GYRE
GYRE
LPRO
LPRO
Q4 25
$-5.6M
$-3.2M
Q3 25
$4.7M
$-5.7M
Q2 25
$2.1M
$848.0K
Q1 25
$-129.0K
$-3.8M
Q4 24
$-2.8M
$17.6M
Q3 24
$1.7M
$11.4M
Q2 24
$-5.5M
$-1.4M
Q1 24
$2.9M
$11.0M
Free Cash Flow
GYRE
GYRE
LPRO
LPRO
Q4 25
$-5.8M
$-3.3M
Q3 25
$4.0M
Q2 25
$1.8M
$837.0K
Q1 25
$-251.0K
$-3.9M
Q4 24
$-2.8M
$17.4M
Q3 24
$1.0M
$11.3M
Q2 24
$-6.9M
$-1.5M
Q1 24
$2.7M
FCF Margin
GYRE
GYRE
LPRO
LPRO
Q4 25
-15.5%
-16.8%
Q3 25
13.1%
Q2 25
6.8%
3.3%
Q1 25
-1.1%
-15.9%
Q4 24
-10.1%
-30.6%
Q3 24
4.1%
48.0%
Q2 24
-27.5%
-5.5%
Q1 24
9.8%
Capex Intensity
GYRE
GYRE
LPRO
LPRO
Q4 25
0.4%
0.3%
Q3 25
2.2%
0.0%
Q2 25
1.0%
0.0%
Q1 25
0.6%
0.2%
Q4 24
0.2%
-0.3%
Q3 24
2.7%
0.5%
Q2 24
5.8%
0.2%
Q1 24
0.9%
0.0%
Cash Conversion
GYRE
GYRE
LPRO
LPRO
Q4 25
Q3 25
0.79×
Q2 25
1.32×
0.82×
Q1 25
-0.03×
-6.22×
Q4 24
-4.85×
Q3 24
0.60×
7.92×
Q2 24
-1.21×
-0.48×
Q1 24
0.29×
2.16×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons